Home / Market News / $ALNY

$ALNY news and market catalysts

The 38 most recent market catalysts affecting $ALNY, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

38 catalysts 6 high impact 14 bullish 15 bearish Biotechnology
Nov 19, 2026 Corporate Catalyst Bullish Impact 75
FDA Approves Alnylam-Discovered RNAi Therapeutic Livsayis™ (cemdisiran) for Generalized Myasthenia Gravis
Alnylam Pharmaceuticals announced that its RNAi therapeutic, Livsayis (cemdisiran), received FDA approval for generalized myasthenia gravis. This is a significant positive developm…
Nov 12, 2026 Corporate Catalyst Neutral Impact 55
Alnylam Pharmaceuticals Insider Purchases Shares
An insider at Alnylam Pharmaceuticals acquired $299,526 worth of company shares, as disclosed in a recent SEC filing. This transaction is generally interpreted as a vote of confide…
Nov 12, 2026 Corporate Catalyst Bearish Impact 75
Pomerantz LLP Investigates Alnylam Pharmaceuticals, Inc. for Potential Securities Fraud
Pomerantz LLP announced an investigation into Alnylam Pharmaceuticals for potential securities fraud. This action follows a substantial decline in Alnylam's stock price on October …
Nov 10, 2026 Corporate Catalyst Bullish Impact 75
Alnylam Collaborator Regeneron Reports Positive First-in-Human Results for CIDEBsiRNA
Alnylam's collaborator, Regeneron, reported promising first-in-human results for CIDEBsiRNA, an RNAi therapeutic targeting MASLD. The study showed a single dose rapidly normalized …
Nov 10, 2026 Corporate Catalyst Bearish Impact 55
Citigroup Adjusts Alnylam Pharmaceuticals Price Target
Citigroup's decision to reduce Alnylam Pharmaceuticals' price target from $320 to $250 signals a more cautious stance from the analyst firm regarding the company's future valuation…
Nov 9, 2026 Corporate Catalyst Bullish Impact 85
Alnylam Reports Positive Five-Year HELIOS-B Data for Amvuttra
Alnylam Pharmaceuticals announced compelling five-year data from its HELIOS-B study for Amvuttra in ATTR-CM patients. The continuous treatment group demonstrated a 48% reduction in…
Nov 9, 2026 Corporate Catalyst Bearish Impact 65
Truist Securities Downgrades Alnylam Pharmaceuticals
Truist Securities downgraded Alnylam Pharmaceuticals (ALNY) from Buy to Hold and significantly reduced its price target from $315 to $225. This analyst action indicates a revised, …
Nov 9, 2026 Corporate Catalyst Bullish Impact 75
Alnylam-Licensed Elebsiran Shows Positive Results in Phase 3 ECLIPSE 1 Trial for Hepatitis Delta
Alnylam Pharmaceuticals announced that its licensed investigational siRNA, Elebsiran, achieved all primary endpoints in the Phase 3 ECLIPSE 1 trial for Hepatitis Delta. This is a s…
Nov 4, 2026 Corporate Catalyst Bullish Impact 75
Alnylam Pharmaceuticals Announces $1 Billion Share Repurchase Program and Commercial Leadership Transition
Alnylam Pharmaceuticals authorized a $1 billion share repurchase program, a move that typically signals management's belief that the stock is undervalued and can boost shareholder …
Nov 3, 2026 Corporate Catalyst Neutral Impact 55
Alnylam Pharmaceuticals to Present New Clinical and Real-World Data at AHA and ISA 2026
Alnylam Pharmaceuticals is set to present new clinical and real-world data at the AHA and ISA conferences in November 2026. This includes five-year data from the HELIOS-B study and…
Nov 2, 2026 Corporate Catalyst Bearish Impact 75
Truist Securities Downgrades Alnylam Pharmaceuticals to Hold
Truist Securities downgraded Alnylam Pharmaceuticals (ALNY) from a Buy to a Hold rating on November 2, 2026, simultaneously slashing its price target by 28.6% from $315 to $225. Th…
Oct 31, 2026 Corporate Catalyst Neutral Impact 75
Multiple Analysts Adjust Alnylam Pharmaceuticals Price Targets Following Q3 Earnings
Multiple analysts revised their price targets for Alnylam Pharmaceuticals downwards after the company's third-quarter earnings release. This widespread reduction, even from firms m…
Oct 30, 2026 Corporate Catalyst Bearish Impact 85
Bernstein Downgrades Alnylam Pharmaceuticals to Market Perform
Bernstein analyst Jeffrey Walch downgraded Alnylam Pharmaceuticals (ALNY) to Market Perform from Outperform, slashing the price target from $376 to $199. The core reason for the do…
Oct 30, 2026 Corporate Catalyst Bearish Impact 65
RBC Cuts Price Target on Alnylam Pharmaceuticals to $280
RBC's decision to cut Alnylam Pharmaceuticals' price target from $345 to $280, despite maintaining an 'Outperform' rating, indicates a revised outlook on the company's valuation. T…
Oct 29, 2026 Corporate Catalyst Bullish Impact 85
Alnylam Pharmaceuticals Reports Q3 2026 Financial Results
Alnylam Pharmaceuticals reported Q3 2026 revenue of $1.46 billion, surpassing analyst expectations, driven by a 59% year-over-year increase in sales of its hereditary transthyretin…
Oct 29, 2026 Corporate Catalyst Bullish Impact 65
Alnylam Updates Phase 3 TRITON-CM Study for Nucresiran
Alnylam Pharmaceuticals announced an expansion of its Phase 3 TRITON-CM study for nucresiran, increasing target enrollment by 500 patients. This move indicates a stronger commitmen…
Oct 23, 2026 Corporate Catalyst Bullish Impact 75
Alnylam Announces Positive Initial Phase 1b Data for Brezosiran in Huntington's Disease
Alnylam Pharmaceuticals reported positive initial Phase 1b data for brezosiran, its investigational RNAi therapeutic for Huntington's disease. The drug demonstrated significant red…
Sep 21, 2026 Corporate Catalyst Neutral Impact 55
HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $455 Price Target
This filing reports that HC Wainwright & Co. analyst Patrick R. Trucchio has reiterated a 'Buy' rating for Alnylam Pharmaceuticals (ALNY) and maintained a $455 price target. This a…
Sep 2, 2026 Market Technicals Neutral Impact 55
10 Health Care Stocks Whale Activity In Today’s Session
The filing highlights unusual options activity, often indicative of institutional investors ('whales') taking significant positions. This matters because such large trades can sign…
Sep 2, 2026 Corporate Catalyst Neutral Impact 55
HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $455 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio has reaffirmed a 'Buy' rating and a $455 price target for Alnylam Pharmaceuticals. This is a routine analyst update, indicating that…
Aug 31, 2026 Corporate Catalyst Bullish Impact 65
Reported Earlier, Alnylam Highlights AMVUTTRA Results And New RNAi Approach For High Blood Pressure
Alnylam Pharmaceuticals announced new data at the ESC Congress 2026, showcasing the strength of its RNAi platform for cardiovascular disease. The findings reinforce AMVUTTRA's clin…
Aug 19, 2026 Corporate Catalyst Bullish Impact 75
Alnylam Pharmaceuticals shares are trading higher after BMO Capital initiated coverage on the stock with a Outperform rating and announced a $318 price target.
This headline represents a significant corporate catalyst for Alnylam Pharmaceuticals. Analyst upgrades from reputable firms like BMO Capital often lead to immediate positive price…
Aug 19, 2026 Corporate Catalyst Neutral Impact 55
This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
The filing announces new analyst coverage for five companies, with BMO Capital's David Lebowitz initiating on three of them. For Alnylam Pharmaceuticals (ALNY), Biomarin Pharmaceut…
Aug 19, 2026 Corporate Catalyst Neutral Impact 55
BMO Capital Initiates Coverage On Alnylam Pharmaceuticals with Outperform Rating, Announces Price Target of $318
BMO Capital's initiation of coverage on Alnylam Pharmaceuticals with an 'Outperform' rating and a $318 price target is a positive development for the company. This signals that a p…
Aug 3, 2026 Corporate Catalyst Bullish Impact 55
Raymond James Upgrades Alnylam Pharmaceuticals to Strong Buy, Maintains Price Target to $420
Raymond James analyst Martin Auster upgraded Alnylam Pharmaceuticals (ALNY) from Outperform to Strong Buy, while simultaneously maintaining a $420 price target. This action signals…
Aug 3, 2026 Corporate Catalyst Bearish Impact 65
Alnylam Pharmaceuticals shares are trading higher. Barclays maintained its Overweight rating on the stock and lowered its price target from $527 to $450.
The headline indicates a positive market reaction for Alnylam Pharmaceuticals (ALNY) despite a price target reduction. This suggests that the maintained 'Overweight' rating from Ba…
Aug 3, 2026 Corporate Catalyst Bearish Impact 55
Barclays Maintains Overweight on Alnylam Pharmaceuticals, Lowers Price Target to $450
Barclays analyst Eliana Merle maintained an 'Overweight' rating on Alnylam Pharmaceuticals, signaling continued confidence in the company's fundamentals and future growth. However,…
Jul 31, 2026 Corporate Catalyst Bearish Impact 55
JP Morgan Maintains Overweight on Alnylam Pharmaceuticals, Lowers Price Target to $375
JP Morgan analyst Jessica Fye maintained an 'Overweight' rating on Alnylam Pharmaceuticals, signaling continued confidence in the company's fundamentals and future performance. How…
Jul 31, 2026 Corporate Catalyst Bearish Impact 60
RBC Capital Maintains Outperform on Alnylam Pharmaceuticals, Lowers Price Target to $350
RBC Capital's decision to lower Alnylam Pharmaceuticals' price target by nearly 21% from $445 to $350, despite maintaining an 'Outperform' rating, indicates a reassessment of the c…
Jul 31, 2026 Corporate Catalyst Neutral Impact 65
Morgan Stanley Maintains Equal-Weight on Alnylam Pharmaceuticals, Lowers Price Target to $300
Morgan Stanley analyst Michael Ulz lowered the price target for Alnylam Pharmaceuticals (ALNY) from $400 to $300, while maintaining an 'Equal-Weight' rating. This action indicates …
Jul 31, 2026 Corporate Catalyst Bearish Impact 65
Oppenheimer Maintains Outperform on Alnylam Pharmaceuticals, Lowers Price Target to $350
Oppenheimer analyst Kostas Biliouris maintained an 'Outperform' rating on Alnylam Pharmaceuticals but drastically cut the price target from $500 to $350. This action indicates that…
Jul 30, 2026 Corporate Catalyst Bearish Impact 85
Alnylam Lowers 2026 Outlook As Second-Line Amvuttra Demand Normalizes, Stock Tanks
Alnylam Pharmaceuticals announced a reduction in its fiscal 2026 sales guidance, primarily due to a slowdown in the growth of second-line Amvuttra demand in the ATTR-CM market, whi…
Jul 30, 2026 Corporate Catalyst Bearish Impact 85
Alnylam Pharmaceuticals shares are trading lower after the company reported mixed Q2 financial results and cut its FY26 sales guidance below estimates.
This headline represents a significant corporate catalyst for Alnylam Pharmaceuticals (ALNY). The combination of mixed Q2 results and, more critically, a cut in the FY26 sales guid…
Jul 30, 2026 Corporate Catalyst Bearish Impact 75
Alnylam Pharmaceuticals Lowers FY2026 Sales Guidance from $5.300B-$5.800B to $5.275B-$5.725B vs $5.580B Est
Alnylam Pharmaceuticals announced a reduction in its financial year 2026 sales guidance. The new range of $5.275 billion-$5.725 billion is lower than the previous $5.300 billion-$5…
Jul 30, 2026 Corporate Catalyst Bullish Impact 85
Alnylam Pharmaceuticals Q2 Adj. EPS $1.84 Beats $1.55 Estimate, Sales $1.291B Miss $1.323B Estimate
Alnylam Pharmaceuticals (ALNY) released its Q2 earnings, reporting an adjusted EPS of $1.84, which comfortably surpassed the analyst consensus of $1.55. This represents a remarkabl…
Jul 22, 2026 Corporate Catalyst Bearish Impact 55
JP Morgan Maintains Overweight on Alnylam Pharmaceuticals, Lowers Price Target to $400
JP Morgan analyst Jessica Fye has reiterated an 'Overweight' rating on Alnylam Pharmaceuticals, signaling continued confidence in the company's long-term prospects. However, the ac…
Jul 15, 2026 Corporate Catalyst Bullish Impact 75
Alnylam Highlights Neuroscience Progress At AAIC 2026, Initiating Phase 2 APPlauDS Study Of Mivelsiran In Down Syndrome-Associated Alzheimer's While Completing cAPPricorn-1 Enrollment In CAA
Alnylam has announced significant progress in its neuroscience pipeline for Mivelsiran, a key investigational drug. The initiation of a global Phase 2 study for Mivelsiran in Down …
Jul 13, 2026 Corporate Catalyst Bullish Impact 55
HC Wainwright & Co. Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $485
HC Wainwright & Co. maintaining a 'Buy' rating and raising the price target for Alnylam Pharmaceuticals from $470 to $485 signals a positive outlook from a key analyst. This action…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.